{"meta":{"totalResults":6,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"C225"},{"type":"Synonym","name":"C225 monoclonal antibody"},{"type":"Abbreviation","name":"MOAB C225"},{"type":"Synonym","name":"monoclonal antibody C225"},{"type":"CodeName","name":"IMC-C225"},{"type":"Synonym","name":"Anti-EGFR Monoclonal Antibody"},{"type":"Synonym","name":"Anti-Epidermal Growth Factor Receptor Monoclonal Antibody"},{"type":"USBrandName","name":"Erbitux"},{"type":"Synonym","name":"Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 gamma1-chain), disulfide with human-mouse monoclonal C225 kappa-chain, dimer"},{"type":"Abbreviation","name":"Chimeric MoAb C225"},{"type":"Synonym","name":"Chimeric Anti-EGFR Monoclonal Antibody"},{"type":"Synonym","name":"Chimeric Monoclonal Antibody C225"},{"type":"Synonym","name":"cetuximab biosimilar CMAB009"},{"type":"Synonym","name":"cetuximab biosimilar KL 140"},{"type":"Synonym","name":"cetuximab biosimilar CDP-1"},{"type":"INDCode","name":"3610"},{"type":"INDCode","name":"11460"},{"type":"NSCNumber","name":"714692"},{"type":"CASRegistryName","name":"205923-56-4"}],"definition":{"html":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","text":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/cetuximab","text":"Cetuximab"},"nciConceptId":"C1723","nciConceptName":"Cetuximab","termId":42384,"name":"cetuximab","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cetuximab"},{"aliases":[{"type":"CodeName","name":"ASP 1929"},{"type":"Synonym","name":"cetuximab sarotalocan"},{"type":"Synonym","name":"Cet-IR700"},{"type":"CodeName","name":"ASP1929"},{"type":"Synonym","name":"cetuximab-IR700 conjugate RM-1929"},{"type":"CodeName","name":"RM-1929"},{"type":"CASRegistryName","name":"2166339-33-7"},{"type":"CodeName","name":"ASP-1929"}],"definition":{"html":"The sodium salt form of cetuximab sarotalocan, which consists of a chemical conjugate composed of the dye IR700 linked to cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon injection of cetuximab sarotalocan sodium, the cetuximab moiety targets and binds to EGFR-expressing tumor cells, resulting in the internalization of the conjugate. Upon localized application of near-infrared (NIR) light, the IR700 dye becomes activated, disrupts the cell membrane and selectively kills the EGFR-expressing tumor cells. EGFR, a tyrosine kinase receptor, is overexpressed in a variety of cancers.","text":"The sodium salt form of cetuximab sarotalocan, which consists of a chemical conjugate composed of the dye IR700 linked to cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon injection of cetuximab sarotalocan sodium, the cetuximab moiety targets and binds to EGFR-expressing tumor cells, resulting in the internalization of the conjugate. Upon localized application of near-infrared (NIR) light, the IR700 dye becomes activated, disrupts the cell membrane and selectively kills the EGFR-expressing tumor cells. EGFR, a tyrosine kinase receptor, is overexpressed in a variety of cancers."},"drugInfoSummaryLink":null,"nciConceptId":"C121850","nciConceptName":"Cetuximab Sarotalocan Sodium","termId":771602,"name":"cetuximab sarotalocan sodium","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cetuximab-sarotalocan-sodium"},{"aliases":[{"type":"Synonym","name":"Cetuximab-IRDye800"},{"type":"Synonym","name":"Cetuximab-IRDye800CW"}],"definition":{"html":"An immunoconjugate comprised of the recombinant chimeric monoclonal antibody cetuximab conjugated to the N-hydroxysuccinamide (NHS) ester form of the near-infrared (NIR) fluorescent dye IRDye 800CW (cetuximab-IRDye 800) with potential imaging use. The antibody moiety of cetuximab-IRDye 800 binds to the extracellular domain of the epidermal growth factor receptor (EGFR). Upon binding, IRDye 800 may be detected using NIR imaging, which facilitates the visualization and quantification of EGFR-expressing tumor cells. EGFR is a receptor tyrosine kinase that may be overexpressed on the cell surfaces of various tumor types.\n","text":"An immunoconjugate comprised of the recombinant chimeric monoclonal antibody cetuximab conjugated to the N-hydroxysuccinamide (NHS) ester form of the near-infrared (NIR) fluorescent dye IRDye 800CW (cetuximab-IRDye 800) with potential imaging use. The antibody moiety of cetuximab-IRDye 800 binds to the extracellular domain of the epidermal growth factor receptor (EGFR). Upon binding, IRDye 800 may be detected using NIR imaging, which facilitates the visualization and quantification of EGFR-expressing tumor cells. EGFR is a receptor tyrosine kinase that may be overexpressed on the cell surfaces of various tumor types.\n"},"drugInfoSummaryLink":null,"nciConceptId":"C112499","nciConceptName":"Cetuximab-IRDye 800CW","termId":755023,"name":"cetuximab-IRDye 800","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cetuximab-irdye-800cw"},{"aliases":[{"type":"Synonym","name":"polymeric nanoparticles loaded with cetuximab and decorated with octreotide"},{"type":"Synonym","name":"cetuximab-loaded polymeric nanoparticles decorated with octreotide"}],"definition":{"html":"A preparation of ethylcellulose polymeric nanoparticles loaded with cetuximab, a recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR), and decorated with the somatostatin analog, octreotide, with potential antineoplastic activity. Upon oral administration, the octreotide moiety directs the nanoparticles, which remain inert until a pH of 6.8 is reached, to somatostatin receptors (SSTRs), which are present on the cell membranes of many neuroendocrine tumor (NET) cells. At this pH, cetuximab is selectively released from the ethylcellulose polymer. Cetuximab may then bind to the extracellular domain of EGFR-expressing tumor cells, thereby preventing the activation and subsequent dimerization of the receptor. This may inhibit signal transduction and inhibit tumor cell proliferation in EGFR-dependent tumor cells. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor types.","text":"A preparation of ethylcellulose polymeric nanoparticles loaded with cetuximab, a recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR), and decorated with the somatostatin analog, octreotide, with potential antineoplastic activity. Upon oral administration, the octreotide moiety directs the nanoparticles, which remain inert until a pH of 6.8 is reached, to somatostatin receptors (SSTRs), which are present on the cell membranes of many neuroendocrine tumor (NET) cells. At this pH, cetuximab is selectively released from the ethylcellulose polymer. Cetuximab may then bind to the extracellular domain of EGFR-expressing tumor cells, thereby preventing the activation and subsequent dimerization of the receptor. This may inhibit signal transduction and inhibit tumor cell proliferation in EGFR-dependent tumor cells. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor types."},"drugInfoSummaryLink":null,"nciConceptId":"C158083","nciConceptName":"Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide","termId":797050,"name":"cetuximab-loaded ethylcellulose polymeric nanoparticles decorated with octreotide","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":""},{"aliases":[{"type":"CodeName","name":"HLX07"},{"type":"CodeName","name":"HLX 07"},{"type":"Synonym","name":"cetuximab biobetter HLX07"},{"type":"Synonym","name":"anti-EGFR monoclonal antibody HLX-07"},{"type":"CASRegistryName","name":"2251771-76-1"},{"type":"CodeName","name":"HLX-07"}],"definition":{"html":"A glycoengineered humanized version of the monoclonal antibody of cetuximab, with potential antineoplastic activity. Upon intravenous administration, pimurutamab selectively targets and binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activation and subsequent dimerization of the receptor. This may prevent EGFR-mediated signaling and inhibit EGFR-dependent tumor cell proliferation. In addition, the glyco-optimization promotes antibody-dependent cell-mediated cytotoxicity (ADCC). EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of certain tumor types.","text":"A glycoengineered humanized version of the monoclonal antibody of cetuximab, with potential antineoplastic activity. Upon intravenous administration, pimurutamab selectively targets and binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activation and subsequent dimerization of the receptor. This may prevent EGFR-mediated signaling and inhibit EGFR-dependent tumor cell proliferation. In addition, the glyco-optimization promotes antibody-dependent cell-mediated cytotoxicity (ADCC). EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of certain tumor types."},"drugInfoSummaryLink":null,"nciConceptId":"C163981","nciConceptName":"Pimurutamab","termId":799130,"name":"pimurutamab","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"pimurutamab"},{"aliases":[{"type":"Synonym","name":"zirconium Zr 89 cetuximab"},{"type":"Synonym","name":"zirconium-89-labeled cetuximab"},{"type":"Synonym","name":"cetuximab-zirconium-89"},{"type":"Abbreviation","name":"cetuximab-Zr-89"},{"type":"LexicalVariant","name":"Zirconium Zr 89 Cetuximab"}],"definition":{"html":"A radioimmunoconjugate comprised of  the recombinant chimeric monoclonal antibody cetuximab labeled with the radioisotope zirconium Z 89 (Zr 89) with radioisotopic activity and potential imaging use. The antibody moiety of zirconium Zr 89-cetuximab binds to the extracellular domain of the epidermal growth factor receptor (EGFR). Upon binding, the radioisotope moiety may be detected  using positron emission tomography (PET), allowing the imaging and quantification of EGFR-expressing tumor cells. EGFR is  a tyrosine kinase that may be overexpressed on the cell surfaces of various tumor cell types.","text":"A radioimmunoconjugate comprised of  the recombinant chimeric monoclonal antibody cetuximab labeled with the radioisotope zirconium Z 89 (Zr 89) with radioisotopic activity and potential imaging use. The antibody moiety of zirconium Zr 89-cetuximab binds to the extracellular domain of the epidermal growth factor receptor (EGFR). Upon binding, the radioisotope moiety may be detected  using positron emission tomography (PET), allowing the imaging and quantification of EGFR-expressing tumor cells. EGFR is  a tyrosine kinase that may be overexpressed on the cell surfaces of various tumor cell types."},"drugInfoSummaryLink":null,"nciConceptId":"C78473","nciConceptName":"Zirconium Zr 89 Cetuximab","termId":600183,"name":"zirconium Zr 89-cetuximab","firstLetter":"z","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"zirconium-zr-89-cetuximab"}],"links":null}